or Try an Advanced Search...

    Technical Analysis for ASRT - Assertio Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 0.99 6.44% 0.06
    ASRT closed up 6.44 percent on Friday, May 31, 2024, on 71 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical ASRT trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish 6.44%
    Gapped Up Strength 6.44%
    Oversold Stochastic Weakness 6.44%
    Fell Below 50 DMA Bearish 4.50%
    Stochastic Reached Oversold Weakness 4.50%
    Oversold Stochastic Weakness 4.50%
    20 DMA Resistance Bearish -0.52%
    Older End-of-Day Signals for ASRT ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 1 day ago
    Up 5% 1 day ago
    50 DMA Resistance 1 day ago
    Rose Above Previous Day's High 1 day ago
    Rose Above 50 DMA 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ASRT Chart by TradingView
    Basic chart:

    Profile

    Assertio Therapeutics, Inc. Description

    Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Organ Systems Pain Organic Compounds Chemical Compounds Opioids Potassium Analgesics Acute Pain Neuropathic Pain Migraine Peripheral Neuropathy Amino Acids Diabetic Peripheral Neuropathy Treatment Of Migraine Postherpetic Neuralgia

    Is ASRT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 30 Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
    May 29 Assertio names Brendan O’Grady as its new CEO
    May 29 Assertio Announces the Appointment of Brendan P. O’Grady as New CEO
    May 17 Assertio to Participate in Benchmark Healthcare Conference on May 21-22
    May 17 BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
    May 16 Assertio to Participate in AGP Healthcare Conference on May 21
    May 13 BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS
    May 10 Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
    May 8 Assertio Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
    May 7 Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript
    See more ASRT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.4
    52 Week Low 0.7324
    Average Volume 831,694
    200-Day Moving Average 1.49
    50-Day Moving Average 0.95
    20-Day Moving Average 1.03
    10-Day Moving Average 1.01
    Average True Range 0.07
    RSI (14) 50.98
    ADX 23.34
    +DI 22.88
    -DI 18.52
    Chandelier Exit (Long, 3 ATRs) 1.06
    Chandelier Exit (Short, 3 ATRs) 1.07
    Upper Bollinger Bands 1.15
    Lower Bollinger Band 0.91
    Percent B (%b) 0.36
    BandWidth 23.04
    MACD Line 0.01
    MACD Signal Line 0.02
    MACD Histogram -0.012
    Fundamentals Value
    Market Cap 94.18 Million
    Num Shares 94.7 Million
    EPS -2.74
    Price-to-Earnings (P/E) Ratio -0.36
    Price-to-Sales 0.45
    Price-to-Book 0.39
    PEG Ratio 1.20
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.07
    Resistance 3 (R3) 1.06 1.03 1.06
    Resistance 2 (R2) 1.03 1.01 1.03 1.05
    Resistance 1 (R1) 1.01 1.00 1.02 1.02 1.05
    Pivot Point 0.98 0.98 0.98 0.98 0.98
    Support 1 (S1) 0.96 0.96 0.97 0.97 0.94
    Support 2 (S2) 0.93 0.95 0.93 0.94
    Support 3 (S3) 0.91 0.93 0.93
    Support 4 (S4) 0.92